BridGene Biosciences Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
Series B1
- Latest Deal Amount
-
$28M
- Investors
-
13
BridGene Biosciences General Information
Description
Operator of a biotechnology company intended to develop drugs for traditionally untreatable targets. The company combines technologies, including covalent chemistry, chemical proteomics, and quantitative mass spectrometry, to develop therapeutics and covalent small-molecule inhibitors, enabling healthcare industries to find new drug targets and develop new drugs.
Contact Information
Website
www.bridgenebio.comCorporate Office
- 75 Nicholson Lane
- San Jose, CA 95134
- United States
Corporate Office
- 75 Nicholson Lane
- San Jose, CA 95134
- United States
BridGene Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B1) | 16-Oct-2025 | $28M | Completed | Clinical Trials - Phase 1 | ||
| 4. Early Stage VC (Series B) | 27-Jul-2022 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 05-May-2021 | Completed | Clinical Trials - Phase 1 | |||
| 2. Grant | 18-Sep-2020 | $299K | Completed | Startup | ||
| 1. Grant | 01-Jan-2018 | $223K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
BridGene Biosciences Patents
BridGene Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024434673-A1 | Preparation of compound and crystalline forms thereof | Pending | 20-Mar-2024 | ||
| WO-2025198588-A1 | Preparation of compound and crystalline forms thereof | Pending | 20-Mar-2024 | ||
| AU-2023341864-A1 | Yap/taz-tead oncoproteins inhibitors | Pending | 15-Sep-2022 | ||
| EP-4587424-A1 | Yap/taz-tead oncoproteins inhibitors | Pending | 15-Sep-2022 | ||
| US-20260347319-A1 | Yap/taz-tead oncoproteins inhibitors | Pending | 15-Sep-2022 | C07D205/04 |
BridGene Biosciences Signals
BridGene Biosciences Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bayland Capital | Corporate Venture Capital | Minority | ||
| Gaorong Ventures | Venture Capital | Minority | ||
| Grains Valley Venture Capital | Venture Capital | Minority | ||
| Proxima Capital | Venture Capital | Minority | ||
| Proxima Investments | Venture Capital | Minority |
BridGene Biosciences FAQs
-
When was BridGene Biosciences founded?
BridGene Biosciences was founded in 2018.
-
Where is BridGene Biosciences headquartered?
BridGene Biosciences is headquartered in San Jose, CA.
-
What is the size of BridGene Biosciences?
BridGene Biosciences has 31 total employees.
-
What industry is BridGene Biosciences in?
BridGene Biosciences’s primary industry is Drug Discovery.
-
Is BridGene Biosciences a private or public company?
BridGene Biosciences is a Private company.
-
What is BridGene Biosciences’s current revenue?
The current revenue for BridGene Biosciences is .
-
How much funding has BridGene Biosciences raised over time?
BridGene Biosciences has raised $78.5M.
-
Who are BridGene Biosciences’s investors?
Bayland Capital, Gaorong Ventures, Grains Valley Venture Capital, Proxima Capital, and Proxima Investments are 5 of 13 investors who have invested in BridGene Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process